Obstetrx: Funding, Investors & Team (Aug 2026)
Obstetrx creates a uterine tamponade device to eliminate maternal death and disability from postpartum hemorrhage. In 2014, RevMedx, Inc. developed the XSTAT® hemorrhage-control device in concert with the US military to stop severe bleeding from non-compressible wounds suffered on the battlefield. They soon realized that this type of traumatic bleeding, which XSTAT has been proven successful in treating, is highly analogous to postpartum hemorrhage. Inspired to address this global issue in women’s health, the team quickly got to work adapting the combat medicine technology for an obstetric application. RevMedx partnered with a team from Oregon Health & Science University, who received a Saving Lives at Birth Grand Challenge grant to conduct early-stage research and development. This work culminated in a pre-clinical proof-of-concept study. With the inception of Obstetrx, Inc, a pilot clinical trial was performed in Zambia in 2019. Today, Obstetrx is a privately-held company based in Wilsonville, OR. We are currently working toward regulatory clearance and commercialization of our novel uterine tamponade device in the US and across the globe.
Obstetrx has raised $1.1M across 1 funding round on record, the most recent an Angel of $1.1M announced in Aug 2021.
That round is below the $4.7M median round size for Health Care companies tracked on FundedIQ over the last two years.
Obstetrx Company Profile and Key Stats
Latest funding round on record: Aug 2021.
Obstetrx Funding Rounds
Obstetrx Founders and Leadership Team
No contact details are on record for this team yet.
Obstetrx Funding Compared to Other Health Care Startups
Obstetrx's latest round of $1.1M is below the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Obstetrx in Health Care and Wilsonville
Companies Similar to Obstetrx
https://metriport.com
There are too many reasons why Healthcare is unaffordable in the U.S, but one of the largest is waste. Up to…
Serif Health provides healthcare price intelligence and contract management solution.
Switchboard Health provides virtual care solutions to payers, health systems, employers, and at-risk…
Astek Diagnostics has designed a system that helps doctors choose the right antibiotics for patients…
TECLens is developing a crosslinking technology that can effectively address vision problems in both healthy…
Healthcare Shares operates as a crowdfunding portal for the transformative medical innovations of the future.
Gradient Health collaborates with medical data providers worldwide to assemble diseases and conditions for AI…
Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir’s…
Happy Health is a mission-driven technology company committed to transforming mental health awareness through…
Leal Therapeutics creates new treatments for patients.
Teal Health is on a mission to empower women when it comes to their health – starting with at-home cervical…
Obstetrx Funding FAQs
What does Obstetrx do?
Obstetrx creates a uterine tamponade device to eliminate maternal death and disability from postpartum hemorrhage. In 2014, RevMedx, Inc. developed the XSTAT® hemorrhage-control device in concert with the US military to stop severe bleeding from non-compressible wounds suffered on the battlefield. They soon realized that this type of traumatic bleeding, which XSTAT has been proven successful in treating, is highly analogous to postpartum hemorrhage. Inspired to address this global issue in women’s health, the team quickly got to work adapting the combat medicine technology for an obstetric application. RevMedx partnered with a team from Oregon Health & Science University, who received a Saving Lives at Birth Grand Challenge grant to conduct early-stage research and development. This work culminated in a pre-clinical proof-of-concept study. With the inception of Obstetrx, Inc, a pilot clinical trial was performed in Zambia in 2019. Today, Obstetrx is a privately-held company based in Wilsonville, OR. We are currently working toward regulatory clearance and commercialization of our novel uterine tamponade device in the US and across the globe.
How much funding has Obstetrx raised?
Obstetrx has raised $1.1M across 1 round on record. The most recent is an Angel of $1.1M announced in Aug 2021.
When did Obstetrx last raise funding?
Obstetrx's most recent funding round on record is an Angel of $1.1M, announced in Aug 2021.
Who is the CEO of Obstetrx?
Andrew Barofsky is listed as CEO at Obstetrx.
Where is Obstetrx headquartered?
Obstetrx is based in Wilsonville, Oregon, United States.
How many employees does Obstetrx have?
Obstetrx is in the 1-10 employee band.
How does Obstetrx's funding compare to other Health Care startups?
Obstetrx's latest round of $1.1M is below the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.
About FundedIQ's Obstetrx Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Obstetrx is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.